Effects of Zoledronic Acid on Bone Structure and Organization of Nanocomposites in Rats with Glucocorticoid-Induced Osteoporosis

被引:0
|
作者
Kostyshyn, Nazar [1 ]
Kostyshyn, Liubov [1 ]
Shtablavyi, Igor [2 ]
机构
[1] Danylo Halytsky Lviv Natl Med Univ, Pekarska 69, UA-79010 Lvov, Ukraine
[2] Ivan Franko Natl Univ Lviv, 6 Kyryla & Mefodia, UA-79005 Lvov, Ukraine
来源
关键词
glucocorticoids; zoledronic acid; bone remodeling; bone mineral density; osteoporosis; bone nanocomposites; X-ray diffraction; CRYSTAL SIZE; HYDROXYAPATITE;
D O I
10.33263/BRIAC122.20412049
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Continuous use of methylprednisolone (Mps) is one of the most common causes of secondary' osteoporosis resulting in alterations of the skeleton microstructure and increased fracture risk. The aim of the research as to assess the influence of zoledronic acid on mineral mass. micro- and nanostructure of the bones in rats. which received glucocorticoids. with rats ere randomly divided into three groups: vehicle control. the introduction of methylprednisolone. 3 mg/kg/day (Mps). and Mps combined with zoledronic acid. 0.025 mg/kg (Mps+Zol.). The relative amount of a crystalline component and collagen in the bones was detected by means of X-ray diffraction. microstructure. and calcium level through atomic absorption spectroscopy. Methylprednisolone caused a decrease in the amount of a mineral component in the femoral neck (to -39.8%) in group Mps than vehicle control. It should be emphasized that the introduction of Zol. did not Arm a significant decrease in a mineral component of the bone during the experiment (-11.7% on the 24th day) compared with Mps group, and indices were almost at the same level as in the control group. Zoledronic acid can partially inhibit harmful consequences of glucocorticoids for bone structure in rats and improve mineralization without impairment of crystal parameters of hydroxyapatite lattice.
引用
收藏
页码:2041 / 2049
页数:9
相关论文
共 50 条
  • [41] Glucocorticoid-Induced Osteoporosis
    Humphrey, Mary B.
    Buckley, Lenore
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (14): : 1378 - 1379
  • [42] Glucocorticoid-Induced Osteoporosis
    Buckley, Lenore
    Humphrey, Mary B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2547 - 2556
  • [43] Glucocorticoid-induced osteoporosis
    Manelli, F
    Giustina, A
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (03): : 79 - 85
  • [44] Glucocorticoid-induced osteoporosis
    J. D. Adachi
    Osteoporosis International, 2009, 20 : 239 - 240
  • [45] Glucocorticoid-induced osteoporosis
    Adachi, JD
    Ioannidis, G
    DRUG DEVELOPMENT RESEARCH, 2000, 49 (03) : 120 - 134
  • [46] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    HAHN, BH
    HOSPITAL PRACTICE, 1995, 30 (08): : 45 - &
  • [47] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    Daniel Messina, Osvaldo
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S471 - S471
  • [48] Glucocorticoid-Induced Osteoporosis
    Frenkel, Baruch
    White, Wendy
    Tuckermann, Jan
    GLUCOCORTICOID SIGNALING: FROM MOLECULES TO MICE TO MAN, 2015, 872 : 179 - 215
  • [49] Glucocorticoid-induced osteoporosis
    Saag, KG
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2003, 32 (01) : 135 - +
  • [50] Glucocorticoid-induced osteoporosis
    Sambrook, Philip N.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2008, 11 (04) : 381 - 385